预约演示

更新于：2025-05-07

Eli Lilly Japan KK

子公司|Japan|

www.lilly.co.jp

子公司|Japan|

更新于：2025-05-07

概览

疾病领域	数量

内分泌与代谢疾病	7
神经系统疾病	6
免疫系统疾病	6
肿瘤	5
感染	3
血液及淋巴系统疾病	2

排名前五的药物类型	数量

小分子化药	5
单克隆抗体	4
激素	1
生物类似药	1
重组多肽	1

排名前五的靶点	数量

RET(酪氨酸蛋白激酶受体RET)	1
GIPR x GLP-1R	1
GHR(生长激素受体)	1
5-HT1F receptor(5-羟色胺1F受体)	1
BTK C481S(酪氨酸蛋白激酶BTK C481S)	1

关联

项与 Eli Lilly Japan KK 相关的药物

Donanemab-AZBT

多奈单抗

靶点

pGlu3Aβ

作用机制

焦谷氨酸 (3pE) 修饰型β-淀粉样蛋白抑制剂

在研机构

Eli Lilly & Co. [+3]

原研机构

Eli Lilly & Co.

在研适应症

阿尔茨海默病引起的痴呆症 [+5]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2024-07-02

Lebrikizumab

来金珠单抗

靶点

IL-13

作用机制

IL-13抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2023-11-16

Mirikizumab

米吉珠单抗

靶点

IL-23p19

作用机制

IL-23p19抑制剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2023-03-27

199

项与 Eli Lilly Japan KK 相关的临床试验

JPRN-jRCTs031210129

/ Recruiting临床2期IIT

WJOG14220BClinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive metastatic breast cancer patients - AGAIN

开始日期2021-06-28

申办/合作机构

Eli Lilly Japan KK

JPRN-jRCT2080223988

/ Recruiting临床1期

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 in Japanese Patients with Type 2 Diabetes Mellitus

开始日期2018-07-27

申办/合作机构

Eli Lilly Japan KK

JPRN-jRCT2080223903

/ Recruiting临床3期

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis(I4V-MC-JAHN)

开始日期2018-05-15

申办/合作机构

Eli Lilly Japan KK

100 项与 Eli Lilly Japan KK 相关的临床结果

登录后查看更多信息

0 项与 Eli Lilly Japan KK 相关的专利（医药）

登录后查看更多信息

350

项与 Eli Lilly Japan KK 相关的文献（医药）

2025-04-01·Advances in Therapy

Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study

Article

作者: Potts Bleakman, Alison J ; Redondo, Isabel ; Matsuo, Koji ; Tanaka, Masaru ; Nedeljkovic Protic, Marijana ; Hisamatsu, Tadakazu ; Kobayashi, Taku ; Hibi, Toshifumi ; Hunter Gibble, Theresa ; Osaga, Satoshi

INTRODUCTIONThe global Communicating Needs and Features of Inflammatory Bowel Disease Experiences (CONFIDE) study aimed to evaluate the impact of ulcerative colitis (UC)- and Crohn's disease (CD)-related symptoms on patients' lives and elucidate communication gaps between patients and health care professionals (HCPs). We report the findings from the study in patients with UC or CD and HCPs in Japan.METHODSOnline, quantitative, cross-sectional surveys were conducted in Japan for patients with moderate-to-severe UC or CD and HCPs responsible for the care of patients with UC and/or CD. Subgroup analyses based on disease activity were conducted using the Manitoba Inflammatory Bowel Disease Index. Data were described using descriptive statistics.RESULTSSurveys were completed by 124 patients with UC, 99 patients with CD, and 100 HCPs in Japan. Differences were noted in the most common patient-reported symptoms experienced in the month prior to survey completion between patients with UC and CD (diarrhea [45.2% UC, 68.7% CD], flatulence [34.7% UC, 32.3% CD], increased stool frequency [32.3% UC, 43.4% CD], bowel urgency [BU; 25.0% UC, 32.3% CD], and fatigue [36.4% CD]). More patients with active disease than inactive disease reported these symptoms. BU and BU-related accidents were among the symptoms ranked as most impactful by patients with UC and CD. HCP-perceived symptoms with the greatest impact on patients were diarrhea and blood in stool. Findings in the Japanese cohort of CONFIDE were generally consistent with those in the United States (US)/European cohorts. The percentage of patients reporting BU as the symptom with the greatest impact was higher in the US/European cohorts than in the Japanese cohort, potentially as a result of differences in baseline characteristics and social environments such as toilet facilities.CONCLUSIONBU is an impactful symptom among Japanese patients with UC and CD and should be considered by HCPs during treatment of these conditions.

2025-04-01·Diabetes Therapy

Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis

Article

作者: Hirase, Tetsuaki ; Oura, Tomonori ; Hamamoto, Yoshiyuki

INTRODUCTIONThe objective of this work was to assess the association of tirzepatide with changes in insulin sensitivity and beta-cell function in Japanese patients with type 2 diabetes (T2D).METHODSThis was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D. Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks. Changes from baseline in homeostatic model assessment (HOMA2) parameters were assessed by a mixed model for repeated measures. Post hoc subgroup analyses were conducted based on high and low baseline C-peptide categories (cutoff: median 1.86 µg/l).RESULTSThis analysis included 636 participants (tirzepatide 5 mg: n = 159; 10 mg: n = 158; 15 mg: n = 160; dulaglutide 0.75 mg: n = 159). Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%, - 21.5%, and - 20.7%; p < 0.001 all comparisons). Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B [insulin], 27.3%, 34.9%, and 40.6%; HOMA2-%B [C-peptide], 31.6%, 40.1%, and 46.7%; p < 0.001 all comparisons). Regardless of baseline C-peptide level, the tirzepatide groups showed significant improvement in glycated hemoglobin at week 52 compared with the dulaglutide group (C-peptide < 1.86 µg/l: - 2.31% to - 2.75% vs. - 1.45%; ≥ 1.86 µg/l: - 2.43% to - 2.89% vs. - 1.12%; p < 0.001).CONCLUSIONSIn these prespecified and post hoc analyses, tirzepatide was associated with improved insulin sensitivity and insulin secretion in Japanese participants with T2D, which may result in reduced fasting insulin levels.CLINICALTRIALSGOV: NCT03861052.

2025-03-18·British Journal of Dermatology

Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J)

Article

作者: Tanaka, Akio ; Katoh, Norito ; Kataoka, Yoko ; Shimizu, Ryosuke ; Torisu-Itakura, Hitoe ; Yamamoto, Chie ; Morisaki, Yoji ; Igawa, Ken ; Takahashi, Hidetoshi

AbstractBackgroundModerate-to-severe atopic dermatitis (AD) affects the quality of life of patients. More treatment options are urgently needed to manage this chronic disease. Lebrikizumab is a monoclonal antibody that binds to interleukin-13, a key mediator in AD pathogenesis. In Japanese patients, lebrikizumab has been evaluated through week 16 in the randomized placebo-controlled phase III ADhere-J study.ObjectivesTo evaluate the long-term efficacy and safety of lebrikizumab in combination with topical corticosteroids (TCS) in the ADhere-J study.MethodsPatients aged ≥12 years weighing ≥ 40 kg with moderate-to-severe AD and receiving either subcutaneous lebrikizumab 250 mg every 2 weeks (Q2W)/every 4 weeks (Q4W) or placebo during the 16-week induction period were evaluated during the long-term maintenance period from week 16 to week 68. Responders achieved the co-primary endpoints at week 16: an Investigator’s Global Assessment score of 0 or 1 [IGA (0,1)] with ≥ 2-point improvement from baseline and/or ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI 75). In this analysis, week 16 responders received lebrikizumab 250 mg Q2W or Q4W combined with TCS during the maintenance period (maintenance primary population; MPP); week 16 per-protocol nonresponders received lebrikizumab Q2W with TCS (maintenance escape population; MEP). Major endpoints included IGA (0,1) with ≥ 2-point improvement from baseline and EASI 75 through week 68. Other outcomes included quality of life, itch and serum thymus and activation-regulated chemokine. The trial was registered with ClinicalTrials.gov (NCT04760314).ResultsAt week 68, 66–81% of 103 patients in the MPP and 32–38% of 168 patients in the MEP achieved IGA (0,1) with ≥ 2-point improvement from baseline. EASI 75 was maintained by 83–89% of patients in the MPP, while 71–80% of patients in the MEP achieved this outcome by week 68. Across treatment arms, patients in the MPP tended to maintain improvements recorded at week 16, while patients in the MEP steadily improved across the maintenance period. No new safety signals were reported, and most treatment-emergent adverse events were mild or moderate in severity in both populations. Safety outcomes were consistent with previous reports for lebrikizumab treatment in global studies.ConclusionsThese results support the use of lebrikizumab in combination with TCS for the treatment of moderate-to-severe AD in the Japanese population in the long term.

100 项与 Eli Lilly Japan KK 相关的药物交易

登录后查看更多信息

100 项与 Eli Lilly Japan KK 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年05月10日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

生长激素(Eli Lilly & Co.) ( GHR )	生长激素缺乏症更多	批准上市
依奇珠单抗 ( IL-17A )	红皮病性银屑病更多	批准上市
培美曲塞二钠 ( DHFR x GART x TYMS )	非小细胞肺癌更多	批准上市
来金珠单抗 ( IL-13 )	特应性皮炎更多	批准上市
多奈单抗 ( pGlu3Aβ )	阿尔茨海默症更多	批准上市